Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of “Moderate Buy” by Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has earned an average rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $13.60.

Several analysts have issued reports on OBIO shares. B. Riley Financial dropped their price objective on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Weiss Ratings lowered Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Chardan Capital restated a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, March 12th. Barclays upped their price objective on Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Orchestra BioMed Stock Performance

OBIO opened at $4.24 on Friday. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $5.42. The firm has a market capitalization of $253.90 million, a PE ratio of -4.37 and a beta of 0.50. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03. The business’s 50-day simple moving average is $4.03 and its 200 day simple moving average is $4.19.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.07. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. As a group, sell-side analysts expect that Orchestra BioMed will post -1.47 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jason Aryeh bought 8,971 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $3.90 per share, with a total value of $34,986.90. Following the completion of the transaction, the director owned 117,453 shares of the company’s stock, valued at $458,066.70. This trade represents a 8.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Eric S. Fain bought 20,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was purchased at an average cost of $4.13 per share, for a total transaction of $82,600.00. Following the transaction, the director directly owned 91,709 shares of the company’s stock, valued at $378,758.17. The trade was a 27.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 39,636 shares of company stock valued at $158,081. 7.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Orchestra BioMed

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE grew its position in Orchestra BioMed by 200.7% during the first quarter. Bank of America Corp DE now owns 52,761 shares of the company’s stock worth $224,000 after buying an additional 35,214 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in Orchestra BioMed during the first quarter worth approximately $81,000. Knott David M Jr grew its position in Orchestra BioMed by 1.5% during the first quarter. Knott David M Jr now owns 253,651 shares of the company’s stock worth $1,078,000 after buying an additional 3,651 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in Orchestra BioMed during the first quarter worth approximately $932,000. Finally, Cannon Global Investment Management LLC acquired a new stake in Orchestra BioMed during the first quarter worth approximately $96,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.